Fundraising Fox

PureTech Health

Venture studio

Boston · 11 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

PureTech Health builds and develops novel medicines by identifying patient needs where an existing therapeutic approach has demonstrated human efficacy but is held back by limitations such as off-target effects, low bioavailability, or poor tolerability. Its R&D model rests on three principles: validated efficacy, clear patient benefit, and an efficient, de-risked path to new classes of medicine. Programs are advanced through Founded Entities, exemplified by KarXT (Cobenfy) for schizophrenia, developed in Karuna Therapeutics and later acquired by Bristol Myers Squibb. Other programs include deupirfenidone for idiopathic pulmonary fibrosis and GlyphAllo, an oral allopregnanolone prodrug using its Glyph technology for mental health indications.

Source: firm website, verified Aug 7, 2026.

HQ
Boston, US
Leads rounds
Follows
Tracked investments
5

Team · 11 people

from the firm's website

Investments · 5 tracked

founders shown can be your intro path
Celea Therapeutics

PureTech-founded entity advancing deupirfenidone (via the Phase 3 SURPASS-IPF trial) as a potential new standard of care for idiopathic pulmonary fibrosis.

Gallop Oncology
Karuna
Karuna Therapeutics

PureTech Founded Entity that developed KarXT (Cobenfy) for schizophrenia and was acquired by Bristol Myers Squibb for $14 billion.

Seaport Therapeutics

Frequently asked questions

What sectors does PureTech Health focus on?
PureTech Health focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is PureTech Health located?
PureTech Health is headquartered in Boston, US.
Does PureTech Health lead rounds?
PureTech Health typically participates in rounds rather than leading them.

Similar investors

Featured in lists